Heartbeam, Inc.

Greetings and welcome to the HeartBeam Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. Before we begin the formal presentation, I would like to remind everyone that statements made on the call and webcast may include predictions, estimates, or other information that might be considered forward-looking. why these forward-looking statements represent our current judgment on what the future holds. They are subject to risk and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revisions to these forward-looking statements in light of new information or future events. Throughout today's discussion, we will attempt to present some important factors relating to our business that may affect our predictions. You should also review our most recent Form K-10 and Form 10-Q for more complete discussions of these factors and other risks, particularly under the heading Risk Factors. A press release detailing these results crossed the wires this afternoon at 4.01 p.m. Eastern Time and is available in the Investor Relations section of our company's website, heartbeam.com. Your host today, Branislaw Wydek, Chief Executive Officer and Founder, John Hunt, Chief Business Officer, and Rick Brownstein, Chief Financial Officer, will present results of operations for the third quarter ended September 30th, 2022. At this time, I will turn the call over to HeartBeam Chief Executive Officer Branislaw Wydek. Please go ahead.

Thank you, operator, and good afternoon, everyone. I'm pleased to welcome you to today's third quarter 2022 Financial Results Conference call. I could not be more enthusiastic about the future of HeartBeam, the rapid pace of our product timeline, and our team's ability to scale our commercialization path. For those of you joining us for the first time, I'd like to take a moment to introduce HeartBeam and our opportunity in a short video introduction. The video explores the Harveem Amigo technology, need, market opportunity, and use in heart attack detection. Amigo is the first and only credit card-sized 12 lead ECG device for remote heart attack detection with a 510 regulatory pathway. While we are playing the video for our dial-in participants, unfortunately, It will be about three minutes of silence, but I'd like to remind you that the video is available on our website, heartbeam.com.

Undiagnosed heart attacks can be lethal for individuals and costly to the healthcare system. Today, chest pain is the second most common reason for an ER visit in patients over 45. However, 82% of those visits are unnecessary and cost the healthcare system over $10 billion each year. Because of uncertainty, patients often delay seeking care for an average of three hours, causing a 40% increase in mortality rate. Currently available ECG monitoring solutions are indicated only for screening for arrhythmias, but not for heart attacks. HeartBeam's innovative technology, the HeartBeam AmyGo device, introduces a simple, patient-friendly solution designed specifically for heart attack detection. This credit card-sized device, paired with the smartphone application, puts patients in immediate contact with their care team. The patient places the wireless device on their chest for a 30-second signal recording. The patient's healthcare provider is then notified of the new ECG. To fully characterize the three dimensions of the heart, HeartBeam captures the heart's electrical activity in 3D by recording X, Y, and Z projections into a simple, user-friendly platform. The HeartBeam AMI system provides a comparison of the patient's baseline ECG along with the symptomatic ECG with a marker and a diagnostic suggestion indicating potential heart attack. The results are instantly shared with the patient's care team through the HeartBeam Amy proprietary cloud-based platform. Physicians are aided by a fully autonomous diagnostic system to view the ECG, review diagnostic suggestions, and direct the patient accordingly. Today, clinicians must rely on 12-lead ECG for heart attack detection, performed solely within a hospital or clinic. HeartBeam's Amy and AmyGo technology has the potential to become the standard of care for cardiac patients, with the potential to serve over 18 million patients in the U.S. alone. With a simplified 12-lead ECG process in a portable solution, HeartBeam is poised to revolutionize the healthcare industry by saving lives, reducing costs, improving the patient experience and provider outcomes, while advancing diagnoses with technology that can be used anytime, anywhere. HeartBeam. Putting tomorrow's technology in patients' hands today.